157 related articles for article (PubMed ID: 29404858)
1. Bayesian Networks: A New Approach to Predict Therapeutic Range Achievement of Initial Cyclosporine Blood Concentration After Pediatric Hematopoietic Stem Cell Transplantation.
Leclerc V; Ducher M; Bleyzac N
Drugs R D; 2018 Mar; 18(1):67-75. PubMed ID: 29404858
[TBL] [Abstract][Full Text] [Related]
2. A Clinical Decision Support Tool to Find the Best Initial Intravenous Cyclosporine Regimen in Pediatric Hematopoietic Stem Cell Transplantation.
Leclerc V; Ducher M; Ceraulo A; Bertrand Y; Bleyzac N
J Clin Pharmacol; 2021 Nov; 61(11):1485-1492. PubMed ID: 34105165
[TBL] [Abstract][Full Text] [Related]
3. A decision support tool to find the best cyclosporine dose when switching from intravenous to oral route in pediatric stem cell transplant patients.
Leclerc V; Bleyzac N; Ceraulo A; Bertrand Y; Ducher M
Eur J Clin Pharmacol; 2020 Oct; 76(10):1409-1416. PubMed ID: 32533216
[TBL] [Abstract][Full Text] [Related]
4. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient.
Eljebari H; Gaies E; Fradj NB; Jebabli N; Salouage I; Trabelsi S; Lakhal M; Klouz A
Eur J Clin Pharmacol; 2012 Nov; 68(11):1517-24. PubMed ID: 22527344
[TBL] [Abstract][Full Text] [Related]
6. Bayesian approach for the estimation of cyclosporine area under the curve using limited sampling strategies in pediatric hematopoietic stem cell transplantation.
Sarem S; Li J; Barriere O; Litalien C; Théorêt Y; Lapeyraque AL; Nekka F
Theor Biol Med Model; 2014 Sep; 11():39. PubMed ID: 25192585
[TBL] [Abstract][Full Text] [Related]
7. Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants.
Dupuis LL; Taylor T; Saunders EF
Pharmacotherapy; 2006 Jan; 26(1):15-22. PubMed ID: 16509024
[TBL] [Abstract][Full Text] [Related]
8. Impact of a Bayesian Individualization of Cyclosporine Dosage Regimen for Children Undergoing Allogeneic Hematopoietic Cell Transplantation: A Cost-Effectiveness Analysis.
Beyron C; Ceraulo A; Bertrand Y; Bleyzac N; Philippe M
Ther Drug Monit; 2021 Aug; 43(4):481-489. PubMed ID: 33814541
[TBL] [Abstract][Full Text] [Related]
9. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
11. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation.
Li TF; Hu L; Ma XL; Huang L; Liu XM; Luo XX; Feng WY; Wu CF
Acta Pharmacol Sin; 2019 Dec; 40(12):1603-1610. PubMed ID: 31341257
[TBL] [Abstract][Full Text] [Related]
13. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting.
Charpiat B; Falconi I; Bréant V; Jelliffe RW; Sab JM; Ducerf C; Fourcade N; Thomasson A; Baulieux J
Ther Drug Monit; 1998 Apr; 20(2):158-64. PubMed ID: 9558129
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study on the efficacy and safety of continuous versus twice-daily 3-hour infusion of cyclosporine A in pediatric hematopoietic stem cell transplantation].
Nodomi S; Umeda K; Matsubara H; Daifu T; Kato I; Hiramatsu H; Watanabe K; Heike T; Adachi S
Rinsho Ketsueki; 2012 Nov; 53(11):1891-7. PubMed ID: 23257669
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of limited sampling strategies for estimation of cyclosporine area under the concentration-time curve in hematopoietic stem cell transplant patients.
Hadjibabaie M; Vazirian I; Iravani M; Moosavi SA; Alimoghaddam K; Ghavamzadeh A; Rezaee S
Ther Drug Monit; 2011 Dec; 33(6):673-80. PubMed ID: 22011723
[TBL] [Abstract][Full Text] [Related]
16. Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation.
Dupuis LL; Seto W; Teuffel O; Gibson P; Schultz KR; Doyle JD; Gassas A; Egeler RM; Sung L; Schechter T
Biol Blood Marrow Transplant; 2013 Mar; 19(3):418-23. PubMed ID: 23128321
[TBL] [Abstract][Full Text] [Related]
17. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
18. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
19. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Bleyzac N
Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
[TBL] [Abstract][Full Text] [Related]
20. Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study.
Schechter T; Lewis VA; Schultz KR; Mitchell D; Chen S; Seto W; Teuffel O; Gibson P; Doyle JJ; Gassas A; Sung L; Lee Dupuis L
Pediatr Hematol Oncol; 2018 May; 35(4):288-296. PubMed ID: 30592246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
